| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | S-3ASR |
| 09 Nov 2026 | S-3ASR |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) |
| 30 Oct 2026 | SCHEDULE 13G |
| 05 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THIS STOCK ISSUANCE AGREEMENT (“Agreement”) is entered into as of October 2, 2026, by and between Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”... |
| 15 Sep 2026 |
Form 4: Higgins Jack, Chief Scientific Officer
Received 18,000 shares by exercise or conversion ($24.3K) · Sold 13,200 shares ($334K) · Gave 8,800 shares as a gift · 1 more |
| 11 Sep 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
Form 4: Barchas Isaac, Director
Sold 10,125 shares ($264K) · Sold 62,291 shares ($1.63M) · Sold 11,048 shares ($301K) |
| 12 Aug 2026 | 144 |
| 11 Aug 2026 | S-8 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors |
| 10 Aug 2026 |
Form 4: Barchas Isaac, Director
Sold 20,840 shares ($543K) · Sold 15,248 shares ($397K) |
| 06 Aug 2026 |
Form 4: Horn Kinney, CHIEF BUSINESS OFFICER
Received 90,616 shares by exercise or conversion ($1.08M) · Sold 90,616 shares ($2.27M) |
| 06 Aug 2026 | 144 |
| 04 Aug 2026 | 144 |
Loading...